Abstract
Get full access to this article
View all access options for this article.
References
1.
Lebwohl
MG
,
Stein Gold
L
,
Strober
B
et al. Phase 3 trials of tapinarof cream for plaque psoriasis . N Engl J Med . 2021 ;385 (24 ):2219 –2229 .
2.
Paller
AS
,
Stein Gold
L
,
Soung
J
et al. Efficacy and safety of tapinarof cream for atopic dermatitis: Results from a phase 3 trial . J Am Acad Dermatol . 2023 ;88 (2 ):400 –408 .
3.U.S. Food and Drug Administration . FDA Adverse Event Reporting System (FAERS) . Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-adverse-event-reporting-system-faers-database [Last accessed: January 2 , 2026 .
4.
Bate
A
,
Evans
SJW
Quantitative signal detection using spontaneous adverse drug reaction reporting . Pharmacoepidemiol Drug Saf . 2009 ;18 (6 ):427 –436 .
5.
Alatawi
YM
,
Hansen
RA
Empirical estimation of under-reporting in the FDA Adverse Event Reporting System . Expert Opin Drug Saf . 2017 ;16 (7 ):761 –767 .